To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

And more pharma news updates from Pharmalittle.

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 employees at its headquarters in Nutley, according to a 2025 WARN notice. The ...

MCI and AD dementia affect 22.1M in Europe; Leqembi targets toxic Aβ protofibrils and reduces Aβ plaques. In July 2024, EMA's CHMP adopted a negative opinion for lecanemab approval. 3 Summer ...

(Reuters) -The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a ...

Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. FDA has accepted Eisai's Biologics License Application for lecanemab-irmb, marketed as LEQEMBI, which is designed for subcutaneous ...

A leader in Alzheimer’s research for decades, Eisai is among one of the few pharmaceutical companies with a drug to treat the root causes of a condition that affects more than 55 million people ...

European drug regulators rejected an Alzheimer’s therapy from Eisai Co. and Biogen Inc., a blow to the companies seeking to expand sales in one of the world’s biggest drug markets. The ...